Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy and a tolerable safety profile as second-line HCC treatment. OBJECTIVE: To inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Kudo, Masatoshi, Meyer, Tim, Bai, Yuxian, Guo, Yabing, Meng, Zhiqiang, Satoh, Taroh, Marino, Donatella, Assenat, Eric, Li, Songzi, Chen, Yaxi, Boisserie, Frederic, Abdrashitov, Ramil, Finn, Richard S., Vogel, Arndt, Zhu, Andrew X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557031/
https://www.ncbi.nlm.nih.gov/pubmed/37796513
http://dx.doi.org/10.1001/jamaoncol.2023.4003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557031/
https://www.ncbi.nlm.nih.gov/pubmed/37796513
http://dx.doi.org/10.1001/jamaoncol.2023.4003

Ejemplares similares